Kindred Biosciences (NASDAQ: KIN) is a development-stage biopharmaceutical company taking aim at the $7.5 billion animal health market, specifically focusing on therapies for pets. The company has established a simple, yet effective, strategy to capture its share of the market: leverage investments made in human pharmaceutical R&D to develop therapies that offer the benefits of lower risk, lower cost, and shorter time-to-market. Kindred currently has in development an exciting pipeline of more than 20 programs of high-value products for dogs, cats and horses. The company’s lead candidates are Mirataz™, a weight loss product for cats, and Zimeta™ to treat fever in horses. Kindred has filed NADAs (New Animal Drug Applications) for both candidates, which are in preparations for launch.
To learn more, visit www.kindredbio.com
About Kindred Biosciences
Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.
About NetworkNewsBreak
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com.
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
